The future of anal sex
What EVERY BOOTY should do

Jim Pickett, AIDS Foundation of Chicago
International Rectal Microbicide Working Group
Boston, 24 October 2006
In this section we will cover:

• Who needs rectal microbicides? Who is having anal intercourse (AI)?
• What are the resources needed?
• Who is doing the advocacy work?
• What is the advocacy agenda?
• What can WE do?
How well is this working?

How well is this working Boston?
We need something NEW for our prevention toolbox
Who needs rectal microbicides?

An act of unprotected anal intercourse is 10 – 100 times more likely to result in HIV transmission than an act of unprotected vaginal intercourse.

- **Women/heterosexual**
  - Not well defined, varies
  - Up to 30% of women globally engage in Al
  - 7,794 HIV testing clients in Brazil – 40% Al
  - CSW between Durban and Jo’burg – 43% Al for clients
  - Pop.-based study of 2,547 N. CA women age 19 to 29 – 21.7%
  - Volume unprotected Al (UAI) 7x higher in het compared to gay/MSM
Who needs rectal microbicides?

Gay and MSM still make up the bulk of HIV infections in the West, Latin America, South America.

- Gay men/MSM
  - Among U.S. gay and MSM, most report practicing AI: 76-90%.
  - U.K.: 48.8% UAI (Gay Men’s Sex Survey 2002)
  - U.S.: 48-54% UAI among 4,295 men (EXPLORE Study 2003)
  - STD rates confirm high prevalence of UAI
  - Higher prevalence of HIV compared to heterosexual pop = more risk per act of UAI

*9% of MSM in 2006 received any type of prev (global)
Global Campaign for Microbicides

A worldwide effort co-sponsored by groups working on

- HIV/AIDS
- Reproductive health
- Gay health
- Women’s empowerment
- Prevention

Working to educate, raise awareness and generate collective advocacy for increased political and public investment in microbicide development in the states and the global north and south. Visit the website, endorse the campaign, sign up for their newsletter, host a talk...get involved!

www.global-campaign.org
The Alliance for Microbicide Development is a global, non-profit organization whose sole mission is to speed the development of safe, effective, and affordable microbicides to prevent sexually transmitted infections, most critically HIV/AIDS. The Alliance envisions a world in which all individuals have the power and tools they require to protect themselves from HIV and other sexually transmitted diseases.

www.microbicide.org
International Rectal Microbicides Working Group

- IRMWG formed June 2005
- Over 280 advocates, scientists and policy makers from 32 countries
- Global listserv
- Conference calls featuring scientific presentations – next is Oct 30
- Advocacy agenda supporting the research and development of safe, effective rectal microbicides
- Published “Rectal Microbicides: Investments and Advocacy” in April 2006, M2006 in Cape Town.

www.lifelube.org – more info
jpickett@aidschicago.org – sign up
The mission of the IRMWG

• To promote and facilitate the research and development of safe and effective rectal microbicides for all those that need them
• To promote rectal safety studies on all Phase III vaginal microbicide candidates
• To support the research of other new prevention technologies, such as vaccines and oral prevention (PrEP)
• To promote and disseminate lubricant safety research
• To place rectal microbicides within sexual harm reduction
• To serve as a central forum for exchange, debate, networking on these ideas
• To convene diverse perspectives and scientific disciplines to improve understanding and action
Rectal microbicides must be:

- Safe
- Effective
- Easy to use
Rectal investments

- Total 2000 – 2006 = $34M
- 2000 = $2M and 2006 = $7.2M (est)
Rectal investments

• Public Sector
  • U.S. = $33.1M, 00-06, 97.4%
    • NIH = $30.8M, 00-06
      • 06 = $6.6M
        • .023% of overall budget
      • 07 = $5.5M (projected)
    • CDC = $2.3m, 01-06
      • “The Evaluation of Topical Microbicides in Men Who Have Sex With Men”
        • CDC vaginal - $2.4M, 01-06
          • 12 cents per capita

• Europe?
  • Funds not apportioned specifically, VM $?, Britain’s Microbicide Development Programme - Phase 1 rectal safety study in 06 but investment totals could not be confirmed, other spending too elusive to track…
Rectal investments

• Philanthropic Sector
  • $739,649 - 00-06
    • Approx. 2.2% total funds
    • Trend from 00-06
      • 00 = $337,455
      • 01 = $268,194
      • 02 = $99,000
      • 03 = $0
      • 04 = $10,000
      • 05 = $0
      • 06 = $25,000
  • amfAR primary investor
    • No dedicated RM stream, funding levels fluctuate. RFP released this year for 250k.
    • Direct research support, meeting support.

• Commercial sector
  • $100,000 - 06
    • Most support in-kind
    • Time spent, pipeline compounds, infrastructure.
    • Likely waiting for proof of concept before fiscal risk.
    • Biosyn 06 – $100,000 – in kind
    • Gilead – no figure given

Yoo, hoo... Bill Gates???
Needs estimate

- Conservatively, rectal field probably needs 5 candidates over 10 – 15 year period
- Will require minimum $350M, or at least $35M/year for 10 years
- Annual rectal spending needs to increase 5-fold
FUND THE GAP
Whatever the strategy, the securing of public and private funding for every stage of rectal microbicide R&D must be a priority.
What Can I Do?

Plenty, Sister!
Recommendations from report

• **Advocates must:**
  - Reach out to affected communities to educate and to promote RM trial preparedness.
  - Promote global, national, and regional surveillance efforts to determine percentage of HIV infections attributed to AI in order to better assess the need for RM development.
  - Raise awareness, educate, and mobilize communities to foment a stronger, more visible demand for RM and to elevate the profile of microbicides among policymakers.
  - Ensure linkages to the broader microbicide movement and to advocates working on other prevention technologies.
Recommendations from report

• **Donors must:**
  • Provide a minimum of $350 million for targeted RM research funding over the next 10 to 15 years, or an average of at least $35 million per year to build a comprehensive RM research program.
  • Provide transparency and an increase in institutional commitment to explicitly fund RM development.
  • Commit to supporting phase 1 rectal safety studies for all vaginal microbicide candidates being evaluated in phase 2B/3 efficacy trials.
The U.S. Congress must:

- Pass the Microbicide Development Act, and other countries should consider similar legislation.
Thank you!

Contact info
Jim Pickett
312-334-0920
jpickett@aidschicago.org
www.lifelube.org
www.aidschicago.org